A pilot study led by UCLA Health found that administering an immunotherapy drug in combination with chemotherapy before surgery for people with borderline resectable pancreatic cancer is safe and may improve long-term outcomes. The combination therapy resulted in a higher rate of successful tumor removal, increased time before cancer worsened, and extended overall survival. The trial integrated UCLA research teams and identified changes in anti-tumor immunity that contributed to positive outcomes. This approach, involving PD1-inhibitors, enhances the function of cytolytic T cells and targets potential resistance mechanisms. The study, currently ongoing, opens new avenues for exploring immunotherapy in earlier stages of pancreatic cancer treatment.
Source link
UCLA study finds pre-surgery immunotherapy safe for pancreatic cancer patients
